Comparison of three scoring methods using the FDA-approved 22C3 immunohistochemistry assay to evaluate PD-L1 expression in breast cancer and their association with clinicopathologic factors

Comparison of three scoring methods using the FDA-approved 22C3 immunohistochemistry assay to evaluate PD-L1 expression in breast cancer and their association with clinicopathologic factors

Abstract Background In the evaluation of PD-L1 expression to select patients for anti-PD-1/PD-L1 treatment, uniform guidelines that account for different immunohistochemistry assays, different cell types and different cutoff values across tumor types are lacking. Data on how different scoring method...

Full description

Bibliographic Details
Main Authors: Hua Guo, Qingqing Ding, Yun Gong, Michael Z. Gilcrease, Min Zhao, Jun Zhao, Dawen Sui, Yun Wu, Hui Chen, Hui Liu, Jinxia Zhang, Erika Resetkova, Stacy L. Moulder, Wei-Lien Wang, Lei Huo
Format: Article
Language:English
Published: BMC 2020-06-01
Series:Breast Cancer Research
Subjects:
PD-L1
22C3
Immunohistochemistry
Scoring methods
Breast cancer
Tumor-infiltrating lymphocytes
Online Access:http://link.springer.com/article/10.1186/s13058-020-01303-9

Internet

http://link.springer.com/article/10.1186/s13058-020-01303-9

Similar Items